Stenocare AS Cash Flow Conversion Efficiency
Stenocare AS cash flow conversion efficiency. Based on the latest financial reports, Stenocare AS (STENO) has a cash flow conversion efficiency ratio of 0.180x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr1.54 Million ≈ $241.72K USD) by net assets (Dkr8.59 Million ≈ $1.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Stenocare AS (2018–2025)
Cash flow conversion efficiency of Stenocare AS from 2018 to 2025. This chart illustrates how Stenocare AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View STENO stock price for real-time trading data and today's change.
Stenocare AS Cash Flow Conversion Ratio Explained
Stenocare AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Stenocare AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stenocare AS ranked by their cash flow conversion efficiency. Also see Stenocare AS market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acurx Pharmaceuticals LLC
NASDAQ:ACXP
|
-0.210x |
|
G Capital Public Company Limited
BK:GCAP
|
-0.071x |
|
Lucapa Diamond Company Ltd
AU:LOM
|
-0.039x |
|
RUBIX Resources Ltd
AU:RB6
|
-1.211x |
|
Beowulf Mining PLC
ST:BEO-SDB
|
N/A |
|
Gibb River Diamonds Ltd
AU:GIB
|
-1.410x |
|
Sinergi Inti Plastindo
JK:ESIP
|
0.003x |
|
Polar Capital Global Financials Trust plc
LSE:PCFT
|
0.010x |
Annual Cash Flow Conversion Efficiency for Stenocare AS (2018–2025)
The table below shows the annual cash flow conversion efficiency of Stenocare AS from 2018 to 2025. Review STENO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr9.47 Million ≈ $1.48 Million |
Dkr-7.21 Million ≈ $-1.13 Million |
-0.762x | -137.05% |
| 2024-12-31 | Dkr-3.47 Million ≈ $-543.48K |
Dkr-7.14 Million ≈ $-1.12 Million |
2.056x | +628.68% |
| 2023-12-31 | Dkr25.82 Million ≈ $4.04 Million |
Dkr-10.04 Million ≈ $-1.57 Million |
-0.389x | +37.55% |
| 2022-12-31 | Dkr24.14 Million ≈ $3.78 Million |
Dkr-15.03 Million ≈ $-2.35 Million |
-0.623x | -87.79% |
| 2021-12-31 | Dkr40.24 Million ≈ $6.30 Million |
Dkr-13.34 Million ≈ $-2.09 Million |
-0.332x | -37.22% |
| 2020-12-31 | Dkr52.57 Million ≈ $8.23 Million |
Dkr-12.70 Million ≈ $-1.99 Million |
-0.242x | -27.96% |
| 2019-12-31 | Dkr13.47 Million ≈ $2.11 Million |
Dkr-2.54 Million ≈ $-398.12K |
-0.189x | +30.65% |
| 2018-12-31 | Dkr20.47 Million ≈ $3.20 Million |
Dkr-5.57 Million ≈ $-872.16K |
-0.272x | -- |
About Stenocare AS
Stenocare A/S cultivates, produces, imports, distributes, and sells prescription-based medical cannabis products to patients in Denmark and internationally. It offers medical cannabis oil products, including THC, THC/CBD, and CBD, as well as CBD100 oil products. The company was incorporated in 2017 and is based in Randers, Denmark.